![David McGirr](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David McGirr
Directeur/Bestuurslid bij
RHYTHM PHARMACEUTICALS, INC.
Vermogen: 11 M $ op 31-05-2026
Profiel
David W.
J.
McGirr is currently an Independent Director at Rhythm Pharmaceuticals, Inc. since 2015.
Formerly, the roles include Chief Executive Officer at Cubist Pharmaceuticals LLC from 2013 to 2014; President & Chief Executive Officer at GAB Robins North America, Inc. from 1997 to 1999; Director at LifeCell Corp.
from 2007 to 2008; Independent Director at Sorrento Tech, Inc. from 2013 to 2018; Independent Director at Relypsa, Inc. from 2013 to 2016; President, Chief Operating Officer & Director at Hippo, Inc. from 1999 to 2002; Independent Director at Arsanis, Inc. from 2017 to 2019; Independent Director at Menlo Therapeutics, Inc. from 2017 to 2020; Independent Director at X4 Pharmaceuticals, Inc. from 2017 to 2025; Director at Roka Bioscience, Inc. from 2013 to 2018; Independent Director at Insmed, Inc. from 2013 to 2026; Chief Financial & Administrative Officer, MD at S.G.
Warburg Group Plc from 1992 to 1995; and Chief Financial & Administrative Officer, MD at S.G.
Warburg & Co., Inc. from 1992 to 1995.
Education includes an undergraduate degree from the University of Glasgow in 1976 and an MBA from The Wharton School of the University of Pennsylvania in 1978.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
INSMED INCORPORATED 0,04% | 06-03-2026 | 92.665 ( 0,04% ) | 10 M $ | 31-05-2026 |
| 24-06-2026 | 11.712 ( 0,02% ) | 1 M $ | 31-05-2026 | |
| 09-06-2025 | 4.722 ( 0,01% ) | 20 352 $ | 31-05-2026 |
Actieve functies van David McGirr
| Bedrijven | Functie | Begin |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-11-2015 |
Eerdere bekende functies van David McGirr
| Bedrijven | Functie | Einde |
|---|---|---|
| INSMED INCORPORATED | Directeur/Bestuurslid | 13-05-2026 |
| X4 PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 22-08-2025 |
| VYNE THERAPEUTICS INC. | Directeur/Bestuurslid | 09-03-2020 |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Directeur/Bestuurslid | 01-03-2019 |
| SORRENTO TECH INC | Directeur/Bestuurslid | 01-01-2018 |
Opleiding van David McGirr
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
65
Eerstegraads connecties
16
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 16 |
|---|---|
LifeCell Corp.
 LifeCell Corp. BiotechnologyHealth Technology Develops and markets tissue repair products | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Insmed, Inc.
 Insmed, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases | Health Technology |
Sorrento Tech, Inc.
 Sorrento Tech, Inc. Medical SpecialtiesHealth Technology Develops molecular assays and instrument systems for the food safety industry | Health Technology |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of serlopitant products | Health Technology |
Rhythm Pharmaceuticals, Inc.
 Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
University of Glasgow
 University of Glasgow Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
S.G. Warburg Group Plc
 S.G. Warburg Group Plc Investment Banks/BrokersFinance Provides investment banking services | Finance |
GAB Robins North America, Inc.
 GAB Robins North America, Inc. Insurance Brokers/ServicesFinance Provides insurance claim services | Finance |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops non-absorbed polymeric drugs for applications in cardiovascular and renal diseases | Health Technology |
Hippo, Inc.
 Hippo, Inc. Internet RetailRetail Trade Engages in online retail of bellman carts and waste receptacles | Retail Trade |
S.G. Warburg & Co., Inc.
 S.G. Warburg & Co., Inc. Investment Banks/BrokersFinance Investment bank | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Roka Bioscience, Inc.
 Roka Bioscience, Inc. BiotechnologyHealth Technology Develops highly accurate molecular assays and instrument systems | Health Technology |
Kies MarketScreener 
